Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

George Somlo, MD, Paul Frankel, PhD, Ricardo Spielberger, MD, Chatchada Karanes, MD, Amrita Krishnan, MD, Pablo Parker, MD, Leslie Popplewell, MD, Firoozeh Sahebi, MD, Timothy Schultheiss, PhD, Neil Martin Kogut, MD, David S. Snyder, MD, Anthony Selwyn Stein, M.D., Stephen J. Forman, MD, Jeffrey Wong, MD

Blood (2012) 120 (21): 3151.

https://doi.org/10.1182/blood.V120.21.3151.3151

Published: 2012

Journal Articles

Conditional Survival and Cause-Specific Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Hematologic Malignancy Over Three Decades

Saro H. Armenian, DO, MPH, Can-Lan Sun, Ph.D, Tabitha Vase, George Mills, III, Liezl Atencio, Liton Francisco, Jocelynne Palmer, PhD, Ari VanderWalde, MD, MPH, F. Lennie Wong, PhD, Joseph Rosenthal, MD, Neil Martin Kogut, MD, Leslie Popplewell, MD, David S. Snyder, MD, Anthony Selwyn Stein, M.D., Margret O'Donnell, MD, Stephen J. Forman, MD, Smita Bhatia, MD, MPH

Blood (2012) 120 (21): 606.

https://doi.org/10.1182/blood.V120.21.606.606

Published: 2012

Journal Articles

Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm

Pamela S. Becker, MD, PhD, Bruno C. Medeiros, MD, Anthony Selwyn Stein, M.D., Frederick R. Appelbaum, MD, Bart L Scott, MD, MS, Colleen Delaney, MD, MSc, Megan Othus, PhD, Paul C. Hendrie, MD, PhD, Kelda M. Gardner, PA-C, Stephen Petersdorf, MD, John M. Pagel, MD, PhD, Roland B. Walter, MD, PhD, Cynthia Parks, Elihu H. Estey, MD

Blood (2012) 120 (21): 3594.

https://doi.org/10.1182/blood.V120.21.3594.3594

Published: 2012

Journal Articles

Cause-Specific Conditional Survival In 2603 Consecutive Patients Undergoing Autologous Hematopoietic Cell Transplantation (aHCT) Over a 20-Year Period

Ari M. Vander Walde, M.D., M.P.H., Can-Lan Sun, Ph.D., Liton Francisco, B.S., Saro Armenian, D.O., M.P.H., Jennifer Berano Teh, M.D., F. Lennie Wong, Ph.D., Neal Kogut, M.D., Amrita Krishnan, M.D., Auayporn Nademanee, M.D., Leslie Popplewell, M.D., Anthony Selwyn Stein, M.D., Stephen J. Forman, M.D., Smita Bhatia

Blood (2010) 116 (21): 933.

https://doi.org/10.1182/blood.V116.21.933.933

Published: 2010

Journal Articles

Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era

Lester A. Laddaran, B.A., Can-Lan Sun, Ph.D., Ari M. VanderWalde, MD, MPH, Liton Francisco, B.S., Saro Armenian, D.O., M.P.H., Jennifer Berano Teh, M.D., F. Lennie Wong, Ph.D., Chatchada Karanes, MD, Neil Martin Kogut, MD, Amrita Krishnan, M.D., Auayporn Nademanee, M.D., Margaret O'Donnell, M.D., F.R.C.P.C., Pablo Parker, M.D., Leslie Popplewell, M.D., Anthony Selwyn Stein, M.D., Stephen J. Forman, M.D., Smita Bhatia

Blood (2010) 116 (21): 902.

https://doi.org/10.1182/blood.V116.21.902.902

Published: 2010

Journal Articles

Extramedullary Relapse Following Reduced Intensity AlloHCT for Adult AML.

Neil Martin Kogut, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS, Joyce Collins, PhD, Margaret O'Donnell, M.D., F.R.C.P.C., Anthony Selwyn Stein, M.D., Ricardo Spielberger, MD, Stephen Forman, MD

Blood (2010) 116 (21): 3467.

https://doi.org/10.1182/blood.V116.21.3467.3467

Published: 2010

Journal Articles

Final Report of a Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation

Mark Kirschbaum, MD, Anthony Selwyn Stein, M.D., Paul Frankel, Leslie Popplewell, M.D., Robert w Chen, Maria L Delioukina, MD, Ryotaro Nakamura, MD, David S. Snyder, MD, Cynthia Slape, Christopher Ruel, Joel Conrad, Auayporn Nademanee, M.D., Stephen Forman, MD

Blood (2010) 116 (21): 528.

https://doi.org/10.1182/blood.V116.21.528.528

Published: 2010

NARROW

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

Conditional Survival and Cause-Specific Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Hematologic Malignancy Over Three Decades

Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm

Cause-Specific Conditional Survival In 2603 Consecutive Patients Undergoing Autologous Hematopoietic Cell Transplantation (aHCT) Over a 20-Year Period

Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era

Extramedullary Relapse Following Reduced Intensity AlloHCT for Adult AML.

Final Report of a Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation

Email alerts

ASH Publications

American Society of Hematology

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

Conditional Survival and Cause-Specific Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Hematologic Malignancy Over Three Decades

Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm

Cause-Specific Conditional Survival In 2603 Consecutive Patients Undergoing Autologous Hematopoietic Cell Transplantation (aHCT) Over a 20-Year Period

Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era

Extramedullary Relapse Following Reduced Intensity AlloHCT for Adult AML.

Final Report of a Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only